"Llc ""Evimed
Welcome,         Profile    Billing    Logout  
 3 Trials 
4 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gladkov, Oleg
NCT02104830: Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Cancer Patients

Active, not recruiting
3
135
RoW
empegfilrastim 6 mg, Extimia, metpegfilgrastim, pegylated filgrastim, peg-GCSF, filgrastim, GCSF, Placebo №1, Placebo №2, empegfilrastim 7,5 mg
Biocad
Chemotherapy-induced Neutropenia
05/14
02/15
LIBRETTO-531, NCT04211337 / 2019-001978-28: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

Checkmark [VIRTUAL] LIBRETTO-531: Selpercatinib in patients with treatment (Tx)-naïve RET-mutant medullary thyroid cancer (MTC)
Checkmark [VIRTUAL] LIBRETTO-531: A Phase III study of selpercatinib vs investigator choice of cabozantinib or vandetanib in patients with multikinase inhibitor-naïve advanced or metastatic RET-mutant medullary thyroid cancer (MTC)
Recruiting
3
400
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib
Loxo Oncology, Inc., Eli Lilly and Company
Medullary Thyroid Cancer
05/24
11/26
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Either Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Checkmark ZEST: Randomized phase III study evaluating efficacy and safety of niraparib in patients with HER2-negative BRCA-mutated or triple-negative breast cancer with detectable circulating tumor DNA after definitive therapy
Recruiting
3
800
Europe, Canada, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
02/25
08/29
COSTAR Lung, NCT04655976 / 2020-003433-37: Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants

Recruiting
2/3
250
Europe, Canada, US, RoW
Cobolimab, Dostarlimab, Docetaxel
GlaxoSmithKline, GlaxoSmithKline Research and Devlopment Limited, GlaxoSmithKline Research and Development Limited
Lung Cancer, Non-Small Cell
09/24
01/26

Download Options